An Official Website of the United States Government
Development of Ultrafine Particles for Intranasal Delivery of Antipsychotics
- Small Business Information
-
Woman-Owned: NoMinority-Owned: YesHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2012Title: Development of Ultrafine Particles for Intranasal Delivery of AntipsychoticsAgency: HHSContract: 1R41MH098521-01Award Amount: $296,413.00
Abstract:
DESCRIPTION: The goal of the proposed project is to develop a biocompatible ultrafine particle-based vector system for the intranasal delivery of clozapine for the pharmacological therapy of treatment- resistant schizophrenic disorders and their associatedsuicidal behavior. The rationale behind the use of intranasal clozapine is grounded on the observation of clozapine's extensive first- pass metabolism associated with buccal intake, clozapine's extensive binding to plasma proteins, its short elimination half-life, the absence of significantly active metabolites, and the potentially serious side effects brought about by the high oral doses required for therapeutic benefit. The LNK Chemsolutions LLC/University of Chicago team will use a series of particle design tools, in vivo, ex vivo and in vitro methods to develop the seminal Phase-I level research. Electrohydrodynamic methods will be used to design particles with well-defined sizes and drug payloads, using three different polymers. In vitro drug releaseexaminations will be complemented by muco-adhesive tests, and ex vivo (swine nasal membrane) drug permeation studies. These will guide in vivo (mouse model) studies aimed at elucidating particle and drug transport. PUBLIC HEALTH RELEVANCE: In this SBIR Phase I grant application, LNK Chemsolutions LLC and the University of Chicago researchers are partnering to develop an intranasal drug delivery platform for one anti-psychotic drug. In vitro and in vivo studies will be performed to investigate the potential of the proposed approach.Small Business Information at Submission:Research Institution Information:LNKCHEMSOLUTIONS
4701 INNOVATION DRIVE LINCOLN, NE 68521-EIN/Tax ID: 147083303DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: YesHUBZone-Owned: NoUNIVERSITY OF CHICAGO
UNIVERSITY OF CHICAGO
5801 S ELLIS AVE
CHICAGO, IL 60637-Contact:
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: |
Program Year/Program: 2012 / STTR |
|
Agency Tracking Number: R41MH098521 |
Solicitation Year: 2012 |
Solicitation Topic Code: NIMH |
Solicitation Number: PA11-133 |